

Cumulative Index 2004

Volume 24

March	ENDOCRINE LABORATORY SCIENCE: TOPICS AT THE INTERFACE OF CLINICAL CARE AND LABORATORY MEDICINE, pages 1–328
June	ANTIMICROBIAL RESISTANCE: CHALLENGES AND SOLUTIONS, pages 329–558
September	EMERGING INFECTIONS AND THEIR CAUSATIVE AGENTS, pages 559–848
December	PATHOLOGY PATIENT SAFETY, pages 849–1064

Note: Page numbers of article titles are in **bold face** type.

A

Acinetobacter, antibiotic-resistant, in pediatric patients, 361

Acquired immunodeficiency syndrome. *See* Human immunodeficiency virus infection.

Acremonium infections, 700–701

Addenda, for reporting results, 929–930

Addison disease, 110–111
 autoantibodies in, 289–291
 in autoimmune polyglandular syndromes, 293–295, 305
 ovarian autoimmunity with, 292, 294

Adherence to procedure, in point-of-care testing, 1003

Adipocytes and adipocytokines, **217–234**
 adiponectin, 222–224, 229
 assays for, 228
 interleukin-6, 226–227, 229
 interleukin-8, 227
 leptin, 219–222, 229
 plasminogen activator inhibitor type 1, 225–226, 229
 resistin, 224, 229
 tumor necrosis factor- α , 224–225, 229

Adiponectin, 222–224, 229

Adipsin, in adipose tissue, 227

Adrenal gland
 congenital hyperplasia of, 112–113
 hormones of, 106–107
 insufficiency of. *See* Addison disease.

Adverse events

 definition of, 981, 998
 impact of, 1025
 in point-of-care testing, 1018

Aeromonas infections, 620–621

African trypanosomiasis, 754–757

Agar screen test, for methicillin susceptibility, 410

Agency for Healthcare Research and Quality, Transforming Health Care Quality through Information Technology program of, 924–925

AIDS. *See* Human immunodeficiency virus infection.

Air travel, infection transmission in, 564

AIRE protein. *See* Autoimmune regulator protein.

Aldosterone, 106
 excess of, 109–110
 transport of, 108

Alkaline phosphatase, bone, in osteoporosis, 187–188

Alveolar echinococcosis, 828–829

Ambler classification, of beta-lactamases, 345–346

Amendments, for reporting results, 929–930

American trypanosomiasis (Chagas' disease), 760–763, 813–814

- Amoxicillin
 for respiratory tract infections
 distribution of, 486
 dosing of, 485, 490, 492, 494
 resistance to, 495
 susceptibility testing of, 501–528
- Amoxicillin/clavulanate, **529–549**
 development of, beta-lactam resistance
 and, 530–536
 extended-release, 539–544
 for pneumonia, 537–539, 541–544
 for respiratory tract infections,
 490–491
 for rhinosinusitis, 536–537, 539–544
 pharmacokinetics of, 540
 resistance to, 495
 susceptibility testing of, 501–528
- Amp C beta-lactamases
 (cephalosporinases), 346, 348–353
- Amphotericin B, resistance to, 723
- Ampicillin, susceptibility testing of, 501–528
- Analog direct immunoassay, for
 testosterone, 122–123
- Analytic errors
 definition of, 981
 detection and reduction of, 1026–1027
 informatics for, 929–933
 Q-PROBES and Q-TRACKS
 programs for, 972–974
 frequency of, 1026
 in point-of-care testing, 1006,
 1008–1009, 1011
- Analytical isoelectric focusing, for
 beta-lactamase identification, 353
- Anaplasma* infections, 639–642, 811
- Anatomic pathology, errors in,
849–863, 972–974
 definition of, 849–850
 detection and reduction of
 changing pathology practice due
 to, 857–858
 conference review method for,
 854–856
 cytologic–histologic correlation
 method for, 851–854
 lean production methods in. *See*
under Lean production
 methods.
 methods for, 850
 root cause analysis for, 857
 Web-based systems for, 858,
 937–938
 identification, 987–988
 multi-institutional study of, 851
 statistics on, 850
 types of, 849–850
- Androgens, 107. *See also* Testosterone.
 priming with, for growth hormone
 testing, 155
 transport of, 108–109
- Andropause, Leydig cell functional
 evaluation in, 126–130
- Angiotensinogen, in adipose tissue, 227
- Animals, infections due to. *See* Zoonoses.
- Anthrax, as bioterrorism agent, 578
- Antibiograms, for antibiotic therapy
 optimization, in critical illness, 331
- Antibiotics, resistance to. *See* Antimicrobial
 resistance.
- Antibody(ies). *See also* Autoimmune
 disorders; *specific antibodies*.
 heterophile, interfering with hormone
 immunoassays, 4–6, 35
 monoclonal. *See* Monoclonal
 antibodies.
 polyclonal, for thyroglobulin, 31–32
- Antifungal agents, resistance to, **721–735**
Aspergillus, 724–725, 728–729
 at cell wall, 725–726
 at cytoplasmic membrane, 723–725
Candida, 722–727
Cryptococcus neoformans, 723–727
 definition of, 721–722
 epidemiology of, 726–730
Fusarium, 729
Pneumocystis jiroveci, 725
Saccharomyces cerevisiae, 725
Scedosporium, 729–730
 susceptibility testing methods for, 722
Trichosporon, 723, 727
 Zygomycetes, 723
- Antigen detection methods, for *Toxoplasma*
gondii, 742
- Antimicrobial resistance. *See also*
 Antifungal agents, resistance to;
specific antibiotics.
 in critical illness, **329–341**
 in emerging infections, 575–576
 in Gram-negative bacteria, in
 hospitalized children, **361–378**
 in *Haemophilus influenzae*,
453–473, **501–528**
 in HIV, 773
 in institutionalized elderly persons,
343–360
 in *Moraxella catarrhalis*. *See*
Moraxella catarrhalis.

- in respiratory pathogens
 amoxicillin/clavulanate evolution
 for, **529–549**
 mechanisms of, **417–451**
 pharmacodynamics and
 pharmacokinetics of,
475–500
- in *Salmonella*, nontyphoidal, 611–612
 in *Staphylococcus aureus*, 442
 methicillin, **401–416**
 vancomycin, **379–400**
- in *Streptococcus pneumoniae*. *See*
Streptococcus pneumoniae.
 selection of, 423–426
- Antiretroviral drugs, HIV resistance to, 773
- APSs (autoimmune polyglandular/
 polyendocrine syndromes), 293–294,
305–317
- Arbovirus infections, geographical
 expansion of, 570–571
- Arginine stimulation test, for growth
 hormone, 150–151, 153–155
- Aspergillus* infections, 695–696, 698–699
 resistance in, 724–725, 728–729
- Association for Pathology Informatics, 920
- Asthma
Chlamydophila pneumoniae in, 635–636
Mycoplasma pneumoniae in, 635–636
- Atherosclerosis, *Chlamydophila pneumoniae*
 in, 637–638
- Athletes, methicillin-resistant
Staphylococcus aureus transmission
 among, 406–407
- Atmospheric pressure photoionization, in
 liquid chromatography-mass
 spectrometry, for steroid hormones,
 114–116
- ATP-binding cassette transporter genes, in
 antifungal resistance, 724
- Autoantibodies, interfering with hormone
 immunoassays, 6–7
- Autoimmune disorders, **275–303**
 Addison disease. *See* Addison disease.
 celiac disease, 287–289
 diabetes mellitus. *See* Diabetes
 mellitus.
 lymphocytic hypophysitis, 295–296
 ovarian, 291–292, 294
 polyglandular, 292–295, **305–317**
 thyroid, 284–287, 291–292, 305
- Autoimmune regulator protein
 distribution of, 307–308
- functions of, 312–313
 gene of, 307
 mutations of, 308–314
 structure of, 307
- Avian influenza, human disease from,
 574–575
- Avidin-biotin-peroxidase method, for
 thyroglobulin, 31–33
- Azithromycin
 for respiratory tract infections
 distribution of, 486
 dosing of, 479–480
 resistance to, 488
 resistance to, 457, 461, 488, 495
 susceptibility testing of, 501–528
- Azoles, resistance to, 724–725
- B**
-
- Babesia* infections, 757–760, 812–813
- Bacillus* infections, transfusion-transmitted,
 809
- Bacterial contamination, of blood
 components, 808–810
- Bar codes, for identification, 927, 993–994,
 1028
- Baylisascaris procyonis* infections, 746–748
- BBL Crystal MRSA ID System, for
 methicillin resistance, 412
- Beef tapeworm infections, 766–768
- Behavioral factors, in emerging infections,
 563, 565–569
- Beta-lactamases
 Amp C type (cephalosporinases),
 347–348
 classification of, 345–346
 description of, 344
 extended spectrum, 346–351
 Gram-negative bacteria, 361–362
Haemophilus influenzae, 421–422, 434
 inhibitors of, 435–436
 molecular epidemiology of, 353–355
Moraxella catarrhalis, 422, 434–435
 nomenclature of, 344–345
 non-SHV, 348
 non-TEM, 348
 respiratory tract pathogens,
 mechanisms of, 427–436
Staphylococcus aureus, in methicillin
 resistance, 403
- Binding proteins, interfering in hormone
 immunoassays, 7–8

Bio-Intact assay, for parathyroid hormone, 202-203

Biometric patient identification systems, 992

Bioprosthetic infections, coagulase-negative streptococcal, 592-593

Biopsy
 in cervical cancer, cytology comparison with, 953-955
 in osteoporosis, 177

Biosite immunofluorescent assay, for B-type natriuretic peptide, 262-264

Bioterrorism, emerging infections due to, 563, 578

Bipolaris infections, 704

Blastoschizomyces capitatus infections, 707

Blood banking
 identification errors in, 983, 986-987
 infections transmitted in. *See* Transfusion-transmitted infections.
 specimen collection errors in, 971-972

Blood culture, specimen collection for, errors in, 971

Blood smear examination
 for *Babesia*, 758-759
 for malaria, 752-753
 for *Trypanosoma brucei*, 756
 for *Trypanosoma cruzi*, 762

Body scan, in thyroid carcinoma, thyroglobulin assay with, 40-41

Bone
 biopsy of, in osteoporosis, 177
 formation of, biochemical markers of, 187-190
 resorption of, biochemical markers of, 179-187

Bone alkaline phosphatase isoenzyme, in osteoporosis, 187-188

Bone mineral density, measurement of, in osteoporosis, 177

Bone sialoprotein, in osteoporosis, 180

Borreliosis (Lyme disease), 810-811

Bronchiolitis and bronchiolitis obliterans
Chlamydomyces pneumoniae in, 637
Mycoplasma pneumoniae in, 637

Bronchoscopes, contaminated, in antibiotic resistance development, 335

Broth microdilution, in susceptibility testing, for methicillin resistance, 410

Burn patients, fungal infections in, 693

Bush-Jacoby-Medeiros classification, of beta-lactamases, 345-346

C

C cells, hyperplasia of, in medullary thyroid carcinoma, 51-52

CA-125, immunoassay for, interference in, 12

Calcitonin, in medullary thyroid carcinoma secretion of, 51 testing for, 66-68

Calcium, urinary, in osteoporosis, 179

Campylobacter infections, 615-618
 clinical features of, 616
 diagnosis of, 616-617
 epidemiology of, 615-616
 microbiology of, 615
 treatment of, 617-618

Campylobacter jejuni infections, water-borne, 568

Cancer

cervical, screening for. *See* Cervical cancer screening.
 fungal infections in, 695

Cancer Checklists, College of American Pathologists, 914-915, 932-933

Candida infections, 694-696, 704-705
 mucocutaneous, in autoimmune polyglandular syndromes, 293-294, 305
 resistance in, 576, 722-727

Candins, resistance to, 725

Carcinoma, thyroid
 medullary. *See* Medullary thyroid carcinoma.
 thyroglobulin measurement in, 29, 31-32, 34, 38-42

Cardiac arrhythmias, ventricular B-type natriuretic peptide in, assays for, 259

Caspofungin, resistance to, 725

Catecholamines, testing for, in pheochromocytoma
 diagnostic value of, 86-89
 versus metanephrines, 91-92

Catheter-related infections
 coagulase-negative streptococcal, 592-593
 fungal, 693-694

Cefaclor, susceptibility testing of, 501-528

- Cefdinir, susceptibility testing of, 501–528
- Cefixime, susceptibility testing of, 501–528
- Cefprozil, susceptibility testing of, 501–528
- Ceftazidime, resistance to, in institutionalized elderly persons, 346, 348–353
- Ceftriaxone
resistance to, *Salmonella*, 612
susceptibility testing of, 501–528
- Cefuroxime, susceptibility testing of, 501–528
- Celiac disease, 287–289
- Cell culture
for filoviruses, 774
for henipaviruses, 777
for monkeypox, 779
- Cell wall, antifungal resistance involving, 725–726
- Cellulitis, *Streptococcus iniae*, 600
- Cephalosporin(s)
resistance to, 346, 348–353, 495
in *Streptococcus pneumoniae*, 420–421
susceptibility testing of, 501–528
- Cephalosporinases (Amp C beta-lactamases), 345–348
- Cervical cancer screening
error detection in, 852–854
in developing countries, **945–963**
appropriate management after, 953–956
outcomes measurement in, 946–947
quality management in, 945–949
of cytology facilities, 950–953
of noncytologic methods, 956–959
target demographic groups in, 949–950
- Cervix, direct inspection of, in cancer screening, 956
- Chagas' disease (American trypanosomiasis), 760–763, 813–814
- Check digit technology, for identification, 992–993
- Chemiluminescent assays, for parathyroid hormone, 201
- Chemistry, identification errors in, 989–990
- Child care arrangements, emerging infections and, 566–567
- Chlamydophila pneumoniae* infections, 633–635
antibiotic therapy for, 490, 494
asthma and, 635–636
atherosclerosis and, 637–638
bronchiolitis and bronchiolitis obliterans and, 637
chronic obstructive pulmonary disease and, 636–637
cystic fibrosis and, 637
diagnosis of, 634–635
multiple sclerosis and, 638
- Chloramphenicol, as protein synthesis inhibitor, 436
- Cholera, 606–608
clinical features of, 607
diagnosis of, 608
epidemiology of, 606
global warming and, 569
microbiology of, 606
non-01 type, 608–609
transmission of, 564
travel-associated, 568–569
treatment of, 608
water-borne, 568–569
- Chromatography
for steroid hormones, 113
gas, with mass spectrometry, for testosterone, 120
high-performance liquid
with electrochemical detection, for metanephrine, 88–89, 93–96
with mass spectrometry
atmospheric pressure photoionization, for steroid hormones, 114–116
for metanephrine, 93–94, 96–100
hydrophobic interaction, for insulin-like growth factor I, 159
thin-layer, for mycobacteria, 652
- Chronic obstructive pulmonary disease
Chlamydophila pneumoniae in, 636–637
Mycoplasma pneumoniae in, 636–637
- Ciprofloxacin, for respiratory tract infections
distribution of, 486
dosing of, 481–482
- Citrobacter*, antibiotic-resistant, in pediatric patients, 361
colonization by, 370
epidemiology of, 362–363

- Cladophialophora bantiana* infections, 704
- Clarithromycin
 for respiratory tract infections
 dosing of, 479–480
 resistance to, 488
 resistance to, 488, 495
 susceptibility testing of, 501–528
- Climatic change, emerging infections and, 563, 569–571
- Clindamycin
 resistance to, 457, 460, 495
 susceptibility testing of, 501–528
- Clinical Context Object Workgroup, 915–916, 928–929
- Clinical Laboratory Improvement
 Amendments of 1988
 point-of-care testing regulations of, 998–1001, 1003–1004, 1011, 1015
 purpose of, 1030
- Clonidine stimulation test, for growth hormone, 151, 153
- Colitis, hemorrhagic, in *Escherichia coli* O157:H7 infections, 613–614
- Collagen cross-links, in osteoporosis, 180, 182–187
- College of American Pathologists
 Cancer Checklists of, 914–915, 932–933
 Q-PROBES and Q-TRACKS
 programs of. *See* Q-Probes and Q-TRACKS programs.
- Colorimetric methods, in metanephrine measurement, 90
- Communication. *See also* Reporting.
 lack of, in health care system, errors resulting from, 1029
 of laboratory data, 917
- Compensation, in heart failure, 238–241
- Competence assessment, in point-of-care testing, 1014
- Competitive immunoassays, for hormones, interferences in, 1–2
- Competitive radioreceptor assay, for thyroid-stimulating hormone receptor antibodies, 285–286
- Complement fixation test, for adrenal hormone antibodies, 290
- Computed tomography, for tapeworm infections, 768
- Concentration-dependent killing, by antibiotics, 480–481
- Conference review, for error detection, 854–855
- Congenital adrenal hyperplasia, 112–113
- Congestive heart failure. *See* Heart failure.
- Connectivity, in point-of-care results transfer, 1010
- Conn's syndrome, 109–110
- Context management, 915–916, 928–929
- Continuous workflow, in lean production, for error reduction, 883, 886–887, 889, 891–897
- COOH-terminal telopeptides, in osteoporosis, 181–185, 187
- CoPath Plus system, for reporting, 930–932
- Coronavirus infections (SARS), 576–577, 780–781, 803–804, 834–835
- Corticosteroids, 106–107
 fungal infections due to, 696
 thyroid function testing effects of, 26
- Corticotropin-stimulation test, for adrenal insufficiency, 111
- Cortisol, 106–107
 excess of, in Cushing's syndrome, 111
 measurement of, in adrenal insufficiency, 110–111
 transport of, 108
- Creutzfeldt-Jacob disease, transfusion-transmitted, 814–817
- Critical illness
 antibiotic-resistant infections in, **329–341**
 epidemiology of, 330
 optimizing therapy for, 330–333
 prevention of, 334–338
 fungal infections in, 693
- “Crossing the Quality Chasm,” 1024
- Cross-reactivity, in hormone immunoassays, 8
- Cryptococcus neoformans* infections, 694, 705–706
 resistance in, 723–727
- Cryptosporidiosis, 568, 744–746
- Culture. *See also* Cell culture.
 bacterial, in blood components, 810
 blood, specimen collection for, errors in, 971

- Ehrlichia*, 642
 fungal. *See specific fungi*.
 urine, specimen collection for, errors
 in, 971
- Curvularia* infections, 704
- Cushing's syndrome, 111
- Cystic fibrosis
Chlamydomydia pneumoniae in, 637
Mycoplasma pneumoniae in, 637
- Cysticercosis, 766–768
- Cytochrome p450 side chain cleavage
 enzyme, antibodies to
 in Addison disease, 290–291
 in polyglandular syndrome, 306
- Cytokines, in adipose tissue. *See* Adipocytes
 and adipocytokines.
- Cytology
 histology correlation with, for error
 detection, 851–854
 identification errors in, 987–988
 in cervical cancer screening. *See*
 Cervical cancer screening.
- Cytomegalovirus infections,
 transfusion-transmitted, 801–802
- Cytoplasmic membrane, antifungal
 resistance involving, 723–725
-
- D**
- Dactylaria gallopavum* infections, 704
- Databases, for medical errors, 858
- Daycare, emerging infections in, 566–567
- Death, from infections, causes of, 560
- Decision support, in error detection and
 reduction, informatics for, 916,
 927–928
- Dehydroepiandrosterone, 107
- Delta checks, for identification error
 detection, 984
- Dematiaceous mold infections, emerging,
 704
- Demographic factors, in emerging
 infections, 562
- Dengue fever, 570, 808
- Deoxyypyridinoline, in osteoporosis,
 181–183, 186
- Dexamethasone suppression test, in
 Cushing's syndrome, 111
- Diabetes mellitus, 275–284
 autoantibodies in
 glutamic acid decarboxylase,
 280–281
 ICA512 (IA-2), 281–282
 in autoimmune polyglandular
 syndromes, 294–295,
 305–306
 insulin, 282–284
 islet cell, 279–280
 types of, 277–278
 environmental triggers of, 276
 genetic determinants of (HLAs), 276
 types of, 275–276
- Diagnostic errors, in pathology. *See*
 Anatomic pathology, errors in.
- Dihydrotestosterone, 107
- Direct immunofluorescence, for islet cell
 antibodies, 279
- Disk diffusion test, for methicillin
 susceptibility, 410
- DNA
 replication of, inhibitors of, in
 antibiotic resistance
 development, 441–443
 translocation of, in antibiotic
 resistance development, 426
- DNA analysis
 for identification error detection, 983
 for monkeypox, 779
 for pituitary hormone genes, 166
 for Rickettsiae, 643
 16S rDNA, for mycobacteria, 651
- DNA gyrase, inhibitors of, 441–442
- L-DOPA stimulation test, for growth
 hormone, 150–151, 153–154
- Doxycycline
 resistance to, 495
 susceptibility testing of, 501–528
- Dual-energy x-ray absorptiometry, in
 osteoporosis, 177
-
- E**
- Ebola virus infections, 773–774,
 832–833
- Echinocandins, resistance to, 725
- Echinococcosis, alveolar, 828–829
- Efflux mechanism, in antibiotic resistance,
 439–440, 442–443, 459
- Ehrlichia* infections, 639–642, 811

- Elderly persons
 in institutions, antibiotic resistance in, **343-360**
 beta-lactamases in, 344-348
 ceftazidime, 346, 348-353
 molecular epidemiology of, 353-355
 surveillance for, 352
 Leydig cell functional evaluation in, 126-130
 thyroid function testing in, 24
- Electrochemiluminescent method
 for B-type natriuretic peptide, 245
 for parathyroid hormone, 201
- Electron microscopy, for microsporidia, 743
- Electronic medical records, 916-917
- Electrophoresis
 for tartrate-resistant acid phosphatase, in osteoporosis, 180
 pulsed-field gel, for beta-lactamase identification, 354
- Emerging infections. *See also specific infections.*
 chronology of, 559-562
 factors affecting, **559-586**
 behavioral, 563, 565-569
 bioterrorism, 563, 578
 child care practices, 566-567
 chronic manifestations of disease, 563, 571-572
 demographic, 562-563
 environmental change, 563, 569-571
 food processing changes, 567-569
 microbial evolution, 563, 574-576
 pathogen detection methods, 563, 572-573
 population distribution, 563-565
 public health system breakdown, 563, 576-578
 sexual behavior, 565-566
 water supply contamination, 567-569
 fungal, **691-719, 721-735**
 gram-negative enteric, **605-626**
 gram-positive, **587-603**
 intracellular bacterial, **627-649**
 mycobacterial, **651-690**
 parasitic, **737-772**
 resistant. *See* Antimicrobial resistance; Antifungal agents, resistance to.
 transfusion-related, 757-763, **797-823**
 viral. *See* Viral infections, emerging.
 zoonoses. *See* Zoonoses, emerging.
- Endocrine disorders
 adipose tissue, **217-234**
 autoantibodies in, **275-303**
 autoimmune polyglandular, 292-295, **305-317**
 growth hormone deficiency, **141-173**
 immunoassays in, interferences in, **1-18**
 natriuretic peptides, **235-274**
 osteoporosis in, **175-197**
 parathyroid hormone, **199-216**
 pheochromocytoma, 61-63, **85-103**
 steroid imbalance, **105-118**
 testosterone abnormalities. *See* Testosterone.
 thyroid carcinoma, **29-47, 49-83**
 thyroid function, **19-28**
- Endomysial autoantibody assay, for transglutaminase antibodies, in celiac disease, 288
- Enteric infections, gram-negative. *See* Gram-negative bacteria, in emerging enteric infections.
- Enterobacter*, antibiotic-resistant, in pediatric patients, 361
 colonization by, 369
 epidemiology of, 362-363, 365
 outbreaks of, 366
- Enterococci, vancomycin-resistant, 380-382
- Enterococcus faecium*, vancomycin-resistant, 575
- Enterotoxins, *Staphylococcus aureus*, 407-408
- Enterovirus infections, transfusion-transmitted, 804-805
- Entomophthorales infections, 701-702
- Environmental change, emerging infections and, 563, 569-571
- "Envisioning a National Health Care Quality Report," 1024-1025
- Enzyme immunoassay
 for *Cryptosporidium parvum*, 745
 for *Mycoplasma pneumoniae*, 632-633
 for Rickettsiae, 645
 for *Toxoplasma gondii*, 742
 for West Nile virus, 783
- Enzyme-linked immunosorbent assay
 for adipocytokines, 228
 for glutamic acid decarboxylase antibodies, in diabetes mellitus, 280-281
 for hantavirus, 776
 for henipaviruses, 777

- for insulin antibodies, 283
 - for tapeworm infections, 768
 - for transglutaminase antibodies, in celiac disease, 288
 - Epinephrine, tumors secreting. *See* Pheochromocytoma.
 - Epstein-Barr virus infections, transfusion-transmitted, 801–802
 - Equilibrium dialysis/ultrafiltration, for testosterone assay, 122
 - ERG11* gene, in antifungal resistance, 724–725
 - erm* genes, in macrolide resistance, 411, 439, 454–458, 462–465
 - Error detection and reduction
 - barriers to, **901–911**
 - fear, 905–908
 - individual, 902–903
 - intolerance of uncertainty, 903–905
 - organizational structure and culture, 908–909
 - systems, 903
 - examination in, **849–863**
 - failure to report errors and, 903–905
 - frequency of errors and, 1025–1026
 - identification type, **979–996**
 - impact of, on patient care, 1025–1030
 - in cervical cancer screening, **945–963**
 - in point-of-care testing, **997–1022**
 - informatics in, **913–943**
 - Institute of Medicine reports on, 913–914, 935–937, 1023–1025
 - laboratory involvement in, **1023–1035**
 - lean production methods for, **865–899**
 - Q-PROBES and Q-TRACKS programs for, **965–978**
 - regulations on, 1030
 - voluntary programs for, 1030–1033
 - Erythromycin
 - for respiratory tract infections, 492, 494
 - mode of action of, 453
 - resistance to
 - epidemiology of, 462–463
 - in *Staphylococcus aureus*, 411
 - in *Streptococcus pneumoniae*, 421
 - mechanisms of, 457, 460
 - susceptibility testing of, 501–528
 - Escherichia coli* infections
 - antibiotic therapy for, 483
 - antibiotic-resistant, in pediatric patients, 364–365
 - O157:H7, 612–614
 - clinical features of, 613–614
 - diagnosis of, 614
 - epidemiology of, 613
 - food-borne and water-borne, 568
 - microbiology of, 612–613
 - treatment of, 614
 - transfusion-transmitted, 809
 - Estradiol, 108
 - Estrogen(s), 108
 - priming with, for growth hormone testing, 155
 - transport of, 108–109
 - European Multiple Endocrine Neoplasia Study Group recommendations, 71, 73–75
 - Euthyroid sick syndrome, thyroid function testing in, 27–28
 - Evolution, microbial, emerging infections from, 574–576
 - Exercise
 - B-type natriuretic peptide effects of, 263
 - in growth hormone provocative testing, 148–149
 - Exophiala* infections, 704
-
- F**
- Familial medullary thyroid carcinoma, 56, 63–70
 - Fatty tissue. *See* Adipocytes and adipocytokines.
 - Fear, as barrier to error detection and reduction, 905–908
 - Filovirus infections, 773–774
 - Fish, *Streptococcus iniae* infections from, 599–600
 - Five percent random review, for postanalytic error detection, 933–934
 - 5S process, in lean production system, for error reduction, 880–890
 - Flavivirus infections, 781–783
 - Flucytosine, resistance to, 726
 - Folic acid metabolism inhibitors, 443
 - Food-borne infections, 567–569
 - gram-negative. *See* Gram-negative bacteria, in emerging enteric infections.
 - Free androgen index, 123–124
 - Free testosterone, 121–124

- Free thyroxine, measurement of
 for screening, 22-23
 in hyperthyroidism, 25-26
 in hypothyroidism, 24-25
 in nonthyroidal illness, 28
 methods for, 21
 reference interval for, 23
- Free triiodothyronine, measurement of
 in hyperthyroidism, 26
 methods for, 21
 reference interval for, 23
- Frozen sections, error detection in, 972-974
- Fungal infections, emerging, **691-719**
Acromonium, 700-701
Aspergillus, 695-696, 698-699
Bipolaris, 704
Blastoschizomyces capitatus, 707
Candida, 694-696, 704-705, 722-727
Cladophialophora bantiana, 704
Cryptococcus neoformans, 694,
 705-706, 723-727
Curvularia, 704
Dactylaria gallopavum, 704
 dematiaceous molds, 704
 Entomophthorales, 701-702
Exophiala, 704
Fusarium, 699, 729
Histoplasma capsulatum, 695, 702-703
 host factors in, 692-696
 cancer, 695-696
 corticosteroids, 696
 critical illness, 693
 HIV infection, 694-695
 immunodeficiency, 694-696
 indwelling catheters, 693-694
 transplantation, 695-696
 hyalohyphomycoses, 697-698
 in HIV infection, 694-695
Malassezia, 707
 Mucorales, 701-702
Paecilomyces, 701
Penicillium marneffeii, 695, 703
Pneumocystis jirovecii, 694, 696-697
Pseudallescheria boydii, 700
Ramichloridium, 704
Rhodotorula, 707
Scedosporium apiospermum, 700
Scopulariopsis, 701, 704
Trichosporon, 706-707
 yeasts, 704-707
 Zygomycetes, 693, 701-702
- Fusarium* infections, 699, 729
- G**
- Gas chromatography/mass spectrometry,
 for testosterone, 120
- Gastroenteritis
 food-borne, 567-569
 gram-negative. *See* Gram-negative
 bacteria, in emerging enteric
 infections.
 water-borne, 567-569
- Gatifloxacin
 for respiratory tract infections, 480,
 491-493
 resistance to, 495
 susceptibility testing of, 501-528
- GBV-C infections, transfusion-transmitted,
 800
- Gemifloxacin
 resistance to, 495
 susceptibility testing of, 501-528
- Genetic factors, in antibiotic resistance, 403,
 408-409, 425-426
- Giardiasis, 568
- Gliadin, antibodies to, in celiac disease, 288
- Global warming, emerging infections and,
 563, 569-571
- Glucagon stimulation test, for growth
 hormone, 151, 154
- Glucocorticoids. *See* Corticosteroids.
- Glucose, monitoring of, in insulin-induced
 growth hormone testing, 149-150,
 152-153
- Glutamic acid decarboxylase antibodies
 in autoimmune polyglandular
 syndromes, 295
 in diabetes mellitus, 280-281
- Gluten enteropathy (celiac disease),
 autoantibodies in, 287-289
- Gonadotropin-releasing hormone,
 age-related changes in, 127-130
- Gonads, dysfunction of, 112
- Graft-versus-host disease, fungal infections
 in, 695
- Gram-negative bacteria
 antibiotic-resistant, in pediatric
 patients, **361-378**
 clinical consequences of, 365-366
 epidemiology of, 362-370
 in chronic care facilities, 370-371
 mechanisms of, 361-362
 outbreaks of, 366-367
 transmission of, 367-370
 in emerging enteric infections, **605-626**
Aeromonas, 620-621

- Campylobacter*, 615–618
Escherichia coli, Shiga toxin-producing, 612–614
Plesiomonas shigelloides, 621–622
Salmonella, nontyphoidal, 609–612
Vibrio, 606–609. *See also* Cholera.
Yersinia enterocolitica, 618–620
- Gram-positive infections, emerging, **587–603**
 coagulase-negative staphylococci, 591–593
Staphylococcus aureus, 588–591
 streptococcal
 group A, 593–596
 group B, 596–598
 groups C and G, 598–599
Streptococcus iniae, 599–600
- Graves disease
 autoantibodies in, 6, 284–286
 hyperthyroidism in, 25–26
- Grepafloxacin, for respiratory tract infections, 481
- Growth hormone, **141–173**
 binding protein of, 165
 deficiency of
 clinical features of
 in adults, 144–146
 in children, 141–144
 genetic analysis in, 166
 diagnosis of
 adult, 144–146
 algorithm for, 166–169
 childhood, 141–144
 insulin-like growth factor I and, 159–166
 isoforms of, 156–157
 measurement of
 methodology for, 146, 157–159
 provocative testing in, 148–156
 arginine, 150–151, 153–155
 clonidine-induced, 151, 153
 L-DOPA, 150–151, 153–154
 exercise, 148–149
 glucagon, 151, 154
 growth hormone secretagogues, 151, 154
 growth hormone-releasing hormone, 151, 154–155
 insulin, 149–150, 152–153
 sex hormone priming in, 155
 spontaneous, 147–148
 replacement of, monitoring with insulin-like growth factor I, 163
 structure of, 146
- Growth hormone-binding protein, interfering in hormone immunoassays, 7
- Growth hormone-releasing hormone, stimulation with, for growth hormone testing, 154–155
-
- ## H
-
- Haemophilus influenzae*
 antibiotic-resistant
 in pneumonia, 539, 541, 544
 macrolides, 453, 457, 459, 461, 465
 mechanisms of, 430, 434, 440, 442–443
 pharmacokinetics and pharmacodynamics and, 487–488
 prevalence of, 419, 421–422, 495, 530, 532–535
 susceptibility testing of, 501–511, 515–517, 520–523
 infections due to, antibiotic therapy for
 dosing in, 490, 494–495
 time-dependent, 478–479
 susceptibility testing of, 501–511, 515–517, 520–523
- Hand antisepsis, for antibiotic-resistant Gram-negative bacteria transmission control, 366–367
- Hantavirus infections, 570, 774–776
- Hashimoto thyroiditis, autoantibodies in, 286–287
- Health Level Seven, 917
- Heart disorders, in children, ventricular B-type natriuretic peptide assays in, 259–260
- Heart failure, **235–274**
 causes of, 236–238
 clinical course of, 238–239
 compensations in, 238–241
 adverse consequences of, 239–240
 protection against, 240–241
 definition of, 235–236
 diagnosis of
 new tests needed for, 244–245
 traditional tools for, 243–244
 epidemiology of, 236
 impact on Americans, 236

- Heart (*continued*)
 ventricular B-type natriuretic peptide
 in
 assays for, 250-254
 at point of care, 260-262
 clinical uses of, 262-265
 for acute management, 254
 for chronic management,
 254-255
 for screening, 255-256
 prognostic value of,
 256-258
 right heart, 255
 with arrhythmias, 259
 biology of, 241-243
 disease severity correlation with,
 246-250
 N-terminal fragment of
 clinical applications of,
 263-265
 disease severity correlation
 with, 247-250
 in acute coronary
 syndromes, 252-253
 in chronic management,
 254-255
 in pediatric patients, 260
 in screening, 255-256
 natriuretic peptide
 correlation with,
 245-246
 prognostic value of, 258
 receptors for, 242-243
 structure of, 240-241
- Hematology, identification errors in,
 989-990
- Hemolytic transfusion reactions, in
 identification errors, 983
- Hemolytic uremic syndrome, in *Escherichia coli* O157:H7 infections, 612-614
- Hemorrhagic colitis, in *Escherichia coli* O157:H7 infections, 613-614
- Hemorrhagic fever
 viral, 773-774
 with renal syndrome, in hantavirus
 infections, 570, 774-776
- Henipavirus infections, 776-777
- Heparin, thyroid function testing effects of,
 27
- Hepatitis A, transfusion-transmitted,
 799-800
- Hepatitis B, transfusion-transmitted,
 799-800
 prevention of, 1027
- Hepatitis C
 chronic manifestations of, 571
 discovery of, 573
 transfusion-transmitted, 800, 1027
- Hepatitis D, transfusion-transmitted, 799
- Hepatitis E, transfusion-transmitted,
 799-800
- Heterophile antibodies, interfering with
 hormone immunoassays, 4-6, 35
- Hexarelin stimulation test, for growth
 hormone, 154
- High-dose hook effect, in thyroglobulin
 assay, 34-35
- Highly complex point-of-care testing, 1000
- High-performance liquid chromatography,
 with electrochemical detection, for
 metanephrine, 88-89, 93-96
- Hirata syndrome (insulin autoimmune
 syndrome), autoantibodies in, 283
- Histomorphometry, in osteoporosis, 177
- Histoplasma capsulatum* infections, 695,
 702-703
- HIV infection. *See* Human
 immunodeficiency virus infection.
- HLAs. *See* Human leukocyte antigens.
- Hormone(s). *See* Endocrine disorders;
specific hormones.
- Hormone immunoassays, interferences in,
1-18
 autoantibodies, 6-7
 binding proteins, 7-8
 competitive, 1-2
 cross-reactivity, 8
 detection and correction of, 10-11
 heterophile antibodies, 4-6, 35
 immunometric, 3-4
 matrix effects, 8-9
 medical significance of, 11-13
 rheumatoid factor, 9-10
- hsp65* gene sequencing, for mycobacterial
 identification, 652
- Human antianimal (heterophile) antibodies,
 interfering with hormone
 immunoassays, 4-6, 35
- Human chorionic gonadotropin,
 immunoassay for, interference in,
 11-12
- Human herpes virus infections, transfusion-
 transmitted, 801-802

- Human immunodeficiency virus infection
 drug-resistant, 773
 emergence of, 560, 565–566
 fungal infections in, 694–695
 leishmaniasis in, 764
 microsporidiosis in, 743
 parasitic infections in, 740–744
 prevention of, blood supply testing for, 1027
 sexual behavior and, 565–566
 toxoplasmosis in, 740–742
 transfusion-transmitted, 800–801
- Human leukocyte antigens
 in autoimmune polyglandular syndromes, 293–295
 in celiac disease, 287–288
 in diabetes mellitus, 276, 283
 in Graves disease, 285
 in thyroiditis, 286
- Human papillomavirus infections, detection of, in cervical cancer screening, 950, 952, 956–959
- Human T-lymphotropic virus infections, transfusion-transmitted, 801
- Hyalohyphomycoses infections, 697–698
- Hydatid disease, alveolar, 828–829
- Hydrophobic interaction chromatography, for insulin-like growth factor I, 159
- 11 β -Hydroxylase, deficiency of, 112–113
- 21-Hydroxylase
 antibodies to
 in Addison disease, 290–292
 in polyglandular syndromes, 306
 deficiency of, 112–113
- 3- β -Hydroxysteroid dehydrogenase, antibodies to, in ovarian autoimmunity, 292
- Hyperaldosteronism, primary, 109–110
- Hyperandrogenism, 112
- Hyperparathyroidism
 in multiple endocrine neoplasia type 2, 63
 surgery for, intraoperative monitoring in, 204–212
- Hyperthyroidism
 in Graves disease, 25–26, 284–287
 thyroid function testing in, 25–26
- Hypoglycemia, insulin-induced, for growth hormone deficiency testing, 149–150, 152–153
- Hypogonadism, 112
- Hypoparathyroidism, in autoimmune polyglandular syndromes, 293–294, 305
- Hypophysitis, lymphocytic, autoantibodies in, 295–296
- Hypothalamic-pituitary axis, dysfunction of, growth hormone deficiency in, 143–145
- Hypothyroidism
 autoimmune, ovarian autoimmunity with, 291–292
 in autoimmune thyroiditis, 286
 thyroid function testing in, 24–25
-
- I**
- I-131 body scan, in thyroid carcinoma, thyroglobulin assay with, 40–41
- IA-2 (protein tyrosine phosphatase-2, ICA512) antibodies, in diabetes mellitus, 281–282
- Identification errors, **979–996**
 conceptual framework for, 980–982
 definitions of, 980–982
 detection of, 974–975, 982–984
 frequency of, 984–990
 in anatomic pathology, 987–988
 in chemistry, 989–990
 in hematology, 989–990
 in microbiology, 989–990
 in point-of-care testing, 1007, 1015–1016
 in transfusion medicine, 983, 986–987
 informatics for, 927–929
 public interest in, 990
 reduction of, 991–994, 1028
 regulations concerning, 990
 taxonomy of, 980–982
 underreporting of, 982–983
 wristband, 968–970, 985–986, 991–992, 1028
- Immulate parathyroid hormone assays, 209–210
- Immune response, to *Mycoplasma pneumoniae*, 631–632
- Immunoassays
 for bone sialoprotein, 180
 for deoxy pyridinoline, 181–183, 186
 for hormones. *See* Hormone immunoassays.
 for luteinizing hormone, 125–126
 for osteocalcin, 188–189
 for pyridinoline, 181–183, 186
 for steroid hormones, 113–116

- Immunoassays (*continued*)
 for tartrate-resistant acid phosphatase, 180
 for testosterone, 120, 122–123
- Immunoblot test, for 3- β -hydroxysteroid dehydrogenase antibodies, in ovarian autoimmunity, 292
- Immunodeficiency. *See also* Human immunodeficiency virus infection.
 fungal infections in, 694–696
- Immunofluorescent antibody assay, for West Nile virus, 783
- Immunoglobulin G, measurement of, for *Trypanosoma cruzi*, 762
- Immunometric assays
 for calcitonin, in thyroid carcinoma, 67–68
 for hormones, interferences in, 3–4
 for insulin-like growth factor I, 159
 for thyroglobulin, in thyroid carcinoma, 33
- Immunoprecipitation assay
 for adrenal hormone antibodies, 290–291
 for glutamic acid decarboxylase antibodies, in diabetes mellitus, 280
 for 3- β -hydroxysteroid dehydrogenase antibodies, in ovarian autoimmunity, 292
- Immunoradiometric assay
 for B-type natriuretic peptide, 245
 for parathyroid hormone, 201, 203
- Indirect fluorescent antibody test
 for *Babesia*, 759
 for *Ehrlichia*, 642
- Indirect immunofluorescent assay
 for adrenal hormone antibodies, 290
 for transglutaminase antibodies, in celiac disease, 288
- Infection control, for antibiotic resistance prevention, 334–336
- Infliximab, fungal infections due to, 696
- Influenza, 778
 outbreaks of, 561
 viral evolution in, 574–575
- Informatics, in error detection and reduction, **913–943**
 analytic, 929–933
 Clinical Context Object Workgroup, 915–916, 928–929
- College of American Pathologists
 Cancer Checklists, 914–915
 decision support, 916, 927–928
 electronic medical records, 916–917
 Health Level Seven, 917
 Institute of Medicine report
 consequences and, 913–914, 935–937, 1023–1025
- JCAHO in. *See* Joint Committee for Accreditation of Health Care Organizations.
- Leapfrog Initiative, 918
 logical observation identifiers names and codes, 918–919
 on-line resources for, 926
 postanalytic, 933–935
 preanalytic, 927–929
 Q-PROBES and Q-TRACKS in. *See* Q-PROBES and Q-TRACKS programs.
 quality assurance and improvement in, 919–920
 root cause analysis in. *See* Root cause analysis.
- Six Sigma approach, 922–923, 1025–1026
- Systemized Nomenclature of Medicine–Clinical Terms, 923–924
 training in, 938–939
 Transforming Health Care Quality through Information Technology, 924–925
 Web-based systems for, 937–938
- Institute of Medicine, health care quality reports of, 913–914, 935–937, 1023–1025
- Insulin
 antibodies to, 282–284
 in growth hormone provocative testing, 149–150, 152–153
- Insulin autoimmune syndrome, 283
- Insulin tolerance test, for growth hormone deficiency, 149–150, 152–153
- Insulin-like growth factor I
 acid labile submit of, 165–166
 action of, 159
 age variations of, 160
 assays for, 159–162
 free, 162–163
 in growth hormone treatment monitoring, 163
 problems with, 160–162
 provocative, 165–166
 standards for, 160–161
 binding protein 2 of, 166

- binding protein 3 of, 163–166
 biologic variability of, 160
- Insulin-like growth factor II, growth hormone and, 166
- Integrated pathology reports, 930–932
- Intelligent Tutoring Systems, 934
- Intensive care unit
 antibiotic-resistant infections in. *See* Critical illness, antibiotic-resistant infections in.
 fungal infections in, 693
- Interleukin-6, in adipocytes, 226–227, 229
- Interleukin-8, in adipocytes, 227
- Interpretation errors, in anatomic pathology, 849–850
- Intracellular bacterial infections, emerging, **627–649**
Anaplasma, 639–642, 811
Chlamydia pneumoniae, 633–638
Ehrlichia, 639–642, 811
 list of, 629–630
Mycoplasma pneumoniae, 630–637
 Rickettsiae, 642–645, 810–811
- Iodide, thyroid function testing effects of, 26–27
- Islet cell autoantibodies, 279–282

J

- Joint Committee for Accreditation of Health Care Organizations
 patient identification goals of, 919–920, 990
 point-of-care testing standards of, 999, 1001

K

- Ketolides
 as protein synthesis inhibitors, 437, 440
 for respiratory tract infections, 481
 macrolide-resistant, 463
- Klebsiella* infections
 antibiotic-resistant, in pediatric patients, 361–362
 epidemiology of, 362–363, 365
 outbreaks of, 366
 transfusion-transmitted, 809
- Klebsiella pneumoniae*
 in environment, 335–336

- infections due to, antibiotic therapy for, 483–484
 resistance to, 348–349

Knowledge engineering, for decision-making, 916

Kost's classification framework, for errors, in point-of-care testing, 1005–1012

L

- Labels, errors involving, 993, 1028. *See also* Identification errors.
- Laboratory Accreditation Program, patient identification standards of, 990
- Laboratory errors, definition of, 980–981
- Laboratory identification errors. *See* Identification errors.
- Laboratory methods
 for *Aeromonas*, 620–621
 for *Anaplasma*, 641–642
 for antifungal resistance, 722
 for *Babesia*, 758–759
 for bacterial blood component contaminants, 810
 for *Campylobacter*, 615–617
 for *Chlamydia pneumoniae*, 634–635
 for *Cryptosporidium parvum*, 745
 for *Ehrlichia*, 641–642
 for *Escherichia coli* O157:H7, 612–614
 for filoviruses, 774
 for fungi. *See specific fungi.*
 for hantavirus, 776
 for henipaviruses, 777
 for HIV, 801
 for *Leishmania*, 764–765
 for malaria, 752–754
 for metapneumovirus, 778
 for monkeypox, 779
 for mycobacteria. *See also specific mycobacteria.*
 biochemical reactions for
 rapidly growing, 656–658
 slowly growing, 654–655
 for *Mycoplasma pneumoniae*, 632–633
 for *Paragonimus*, 749
 for parvovirus B19, 803
 for *Plesiomonas shigelloides*, 621–622
 for Rickettsiae, 643–645
 for *Salmonella*, 609–610
 for staphylococci, coagulase-negative, 591–593
 for *Staphylococcus aureus*, 588–590
 for streptococci
 group A, 594–595
 group B, 597

Laboratory methods (*continued*)
 group C and G, 598
 for *Streptococcus iniae*, 600
 for tapeworm infections, 768
 for *Toxoplasma gondii*, 741–742
 for *Trichomonas vaginalis*, 739
 for *Trypanosoma brucei*, 756
 for *Trypanosoma cruzi*, 762–763
 for *Vibrio cholerae*, 607–608
 for *Vibrio parahaemolyticus*, 608
 for *Vibrio vulnificus*, 609
 for West Nile virus, 783, 807–808
 for *Yersinia enterocolitica*, 618–620

Lapses, definition of, 982

Larva migrans, in *Baylisascaris procyonis* infections, 746–748

Latex antigen test, for *Cryptococcus neoformans*, 706

Lean production methods, for error reduction, **865–899**
 evolution of, 866–867
 in anatomic pathology
 continuous workflow in, 883, 886–887, 889, 891–897
 learning line for, 873–880
 the 5S process in, 880–890
 in health care system, 870, 872
 in manufacturing industry, 866–871

Leapfrog Initiative, 918

Legionella pneumophila, infections due to, antibiotic therapy for, 490, 494

Leishmaniasis, 764–766

Leptin, in adipocytes, 219–222, 229

Levodopa (L-DOPA) stimulation test, for growth hormone, 150–151, 153–154

Levofloxacin
 for respiratory tract infections, 480–481, 491–493
 susceptibility testing of, 501–528

Leydig cell function, tests for, 119–131
 free androgen index, 123–124
 in aging, 126–130
 luteinizing hormone, 124–126
 sex hormone-binding globulin, 124
 testosterone, 119–124

Lincosamides, as protein synthesis inhibitors, 437

Lipodystrophy, leptin deficiency in, 222

Liquid chromatography-mass spectrometry
 atmospheric pressure photoionization, for steroid hormones, 114–116
 for metanephrine, 93–94, 96–100

Litigation, fear of, as barrier to error detection and reduction, 907

Logical observation identifiers names and codes, 918–919

Long-term care, antibiotic resistance in. *See* Elderly persons, in institutions, antibiotic resistance in.

Low-T₃ syndrome, thyroid function testing in, 27–28

Luteinizing hormone, measurement of, in males, 124–126

Lyme disease, 810–811

Lymphocytic hypophysitis, autoantibodies in, 295–296

M

Macrolides, **453–473**. *See also specific drugs*, e.g., Erythromycin.
 as protein synthesis inhibitors, 436–437
 mode of action of, 453–454
 resistance to
 epidemiology of, 462–465
 in *Streptococcus pneumoniae*, 421
 mechanisms of, 454–461
 spectrum of activity of, 454
 structures of, 453–454
 susceptibility testing of, 501–528

Mad cow disease, 814–817

Magnetic resonance imaging, for tapeworm infections, 768

Malaria, 750–754
 clinical features of, 751–752
 current relevance of, 754
 diagnosis of, 752–754
 drug-resistant, 576
 geographical expansion of, global warming and, 569–570
 parasite life cycle in, 750–751
 re-emergence of, 564–565
 transfusion-transmitted, 812

Malassezia infections, 707

Marburg virus infections, 773–774

Mass spectrometry, for steroid hormones, 113–116

Matrix effects
 in hormone immunoassays, 8–9
 in point-of-care testing, 1009

mec gene, in *Staphylococcus aureus*
 methicillin resistance, 403–404, 412

- Medical Device Amendments of 1976, 1030
- Medical errors, definition of, 998
- Medullary thyroid carcinoma, **49–83**
 calcitonin secretion in, testing for, 66–68
 C-cell hyperplasia in, 51–52
 differential diagnosis of, 50
 familial, 56, 63–70
 Hirschsprung's disease with, 60–61
 historical review of, 49–50
 hormonal activity in, 51
 in multiple endocrine neoplasia type 2, 54–63, 68–75
 incidence of, 50
 pathology of, 51–52
 pheochromocytoma with, 61–62
 RET gene mutations in, 57–60, 64–66
 sporadic, 51–54
 survival rate in, 51, 53
 treatment of, 68–75
- Metabolic syndrome, testosterone deficiency in, 130, 132–134
- Metanephrines, testing for, in pheochromocytoma. *See* Pheochromocytoma, biochemical tests for, metanephrines.
- Metapneumovirus infections, 777–778
- Metastasis, from thyroid carcinoma, 32, 38–39, 52–53
- Methicillin
Staphylococcus aureus resistance to. *See* *Staphylococcus aureus*, methicillin-resistant.
 susceptibility testing of, 409–412
- Methylation, ribosomal, in macrolide resistance, 454–457
- Microbiology, identification errors in, 989–990
- Micro-insulin autoantibody assay, 284
- Microscopy
 for *Cryptosporidium parvum*, 745
 for fungal identification. *See* *specific fungi*.
 for *Leishmania*, 764–765
 for malaria, 752–753
 for *Paragonimus*, 749
 for *Toxoplasma gondii*, 741–742
 for *Trichomonas vaginalis*, 739
 for *Trypanosoma brucei*, 756
 for *Trypanosoma cruzi*, 762
- Microsporidiosis, 742–744
- Migration, emerging infections and, 563–565
- Mineralocorticoids, 106
- Minimum inhibitory concentration, of antibiotics
 dosing based on, 332–333, 475, 478–479
 for vancomycin-resistant *Staphylococcus aureus*, 386–389
- Minnesota Society of Thoracic Surgeons database, 937
 on medical errors, 858
- Misidentification. *See* Identification errors.
- Mistakes, definition of, 982
- MK0677, for growth hormone, 154
- Model Performance Evaluation Program, 1030–1032
- Moderate-complexity point-of-care testing, 999–1001
- Monkeypox infections, 778–779, 830–831
- Monoclonal antibodies
 for luteinizing hormone assay, 125–126
 to bone alkaline phosphatase, 187–188
 to telopeptides, 181–185, 187
 to thyroglobulin, 31–33
- Moraxella catarrhalis*
 antibiotic-resistant
 pharmacokinetics and pharmacodynamics and, 488
 prevalence of, 419, 422, 434, 443
 susceptibility testing of, 501–507, 517–523
 infections due to, antibiotic therapy for, 478
 susceptibility testing of, 501–507, 517–523
- Mosquito-borne infections
 dengue fever, 808
 geographical expansion of, global warming and, 569–571
 malaria. *See* Malaria.
 Rift Valley Fever, 826–828
 viral encephalitis, 808
 West Nile virus, 781–783, 805–808
- Moxifloxacin
 resistance to, 495
 susceptibility testing of, 501–528
- MRSA. *See* *Staphylococcus aureus*, methicillin-resistant.

- MRSA-Screen, for methicillin resistance, 412
- Mucocutaneous candidiasis, in autoimmune polyglandular syndromes, 293–294, 305
- Mucorales infections, 701–702
- Multiple endocrine neoplasia type 2, 54–63, 68–75
 calcitonin testing in, 66–68
 classification of, 54–57
 Hirschsprung's disease in, 57–60
 hyperparathyroidism in, 63
 pheochromocytoma in, 61–63
 RET gene mutations in, 57–60, 64–66
 treatment of, 68–75
- Multiple sclerosis, *Chlamydomyxa pneumoniae* in, 638
- mur* genes, *Streptococcus pneumoniae*, 432
- Mutations, in antibiotic resistance
 development, 425–426
 macrolides, 458–459
 prevention of, 481–483
- Mycobacterial infections, emerging, **651–690**
Mycobacterium abscessus, 652, 654, 656–658
Mycobacterium alvei, 652–653, 656–658
Mycobacterium bohemicum, 653, 659
Mycobacterium branderi, 654, 659
Mycobacterium brumae, 656–660
Mycobacterium celatum, 654, 660–661
Mycobacterium chesapeaki, 654, 661
Mycobacterium confluentis, 656–658, 661
Mycobacterium conspicuum, 654, 662
Mycobacterium doricum, 654, 662–663
Mycobacterium elephantis, 663
Mycobacterium genavense, 654, 663–664
Mycobacterium goodii, 656–658, 664–665
Mycobacterium haemophilum, 654, 665–666
Mycobacterium hassiacum, 656–658, 666
Mycobacterium heckeshornense, 654, 666–667
Mycobacterium heidelbergense, 667
Mycobacterium holsaticum, 656–658, 667–668
Mycobacterium immunogenicum, 656–658, 668
Mycobacterium interjectum, 654, 668–669
Mycobacterium intermedium, 654, 669
Mycobacterium kubicae, 654, 670
Mycobacterium lacus, 655, 670
Mycobacterium lentiflavum, 655, 671
Mycobacterium mageritense, 656–658, 671–672
Mycobacterium microti, 655, 672–673
Mycobacterium montefiorensis, 655, 673
Mycobacterium mucogenicum, 673–674
Mycobacterium murale, 656–658, 674
Mycobacterium neoaurum, 656–658, 674–675
Mycobacterium novacastrense, 656–658, 675
Mycobacterium palustre, 655, 675–676
Mycobacterium peregrinum, 656–658, 676
Mycobacterium pinnipedii, 655, 676–677
Mycobacterium septicum, 656–658, 677
Mycobacterium sherrisii, 655, 678
Mycobacterium shimoidei, 655, 678–679
Mycobacterium shottsii, 655, 679
Mycobacterium simiae-like organisms, 655, 679–680
Mycobacterium triplex, 655, 680–681
Mycobacterium tuberculosis subspecies *canetti*, 656–658, 681
Mycobacterium tuberculosis subspecies *caprae*, 655, 681–682
Mycobacterium tusciae, 655, 682–683
Mycobacterium vaccae, 656–658, 683
Mycobacterium wolinskyi, 656–658, 683–684
Mycobacterium tuberculosis, resistance to, pharmacokinetics and pharmacodynamics and, 489
- Mycoplasma pneumoniae* infections, 630–637
 antibiotic therapy for, 490, 494
 asthma and, 635–636
 bronchiolitis and bronchiolitis obliterans and, 638
 chronic obstructive pulmonary disease and, 636–637
 cystic fibrosis and, 638
 diagnosis of, 632–633
 epidemiology of, 632
 pathophysiology of, 630–632

N

National Cancer Centers Network database, 937
 on medical errors, 858

National Report on the Quality of Laboratory Services, 1032–1033

Natriuretic peptide, B-type natriuretic, in heart failure. *See under* Heart failure.

Near misses, definition of, 981

Neck dissection, radical, for medullary thyroid carcinoma, 53–54

Necrotizing fasciitis, streptococcal, 595

Neisseria meningitidis infections, 561

Neonatal intensive care unit, antibiotic-resistant Gram-negative bacteria in, 363–370

Neonates, toxic shock syndrome-like exanthematous disease in, 591

Neurocysticercosis, 766–768

Neutropenia, fungal infections in, 695

NH₂-terminal telopeptides, in osteoporosis, 181–187

Nichols Advantage assay, for parathyroid hormone, 201–202

Nipah virus infections, 776–777, 833–834

Nonthyroidal illness, thyroid function testing in, 27–28

Norepinephrine, tumors secreting. *See* Pheochromocytoma.

Norfloxacin, for respiratory tract infections, 481–482

Nosocomial infections, due to antibiotic-resistant Gram-negative bacteria, in pediatric patients, 361–378

Nucleic acid test (NAT), for West Nile virus, 807–808

Nursing homes, antibiotic resistance in. *See* Elderly persons, in institutions, antibiotic resistance in.

O

Ob gene product (leptin), in adipose tissue, 219–222, 229

Obesity

- adiponectin in, 223–224
- antibiotic pharmacokinetics and pharmacodynamics in, 487
- leptin for, 222
- plasminogen activator inhibitor type 1 in, 225–226, 229
- testosterone deficiency in, 130, 132–134

Omeprazole, for calcitonin testing, 66

Ordering tests, errors in, 927–928, 967–968

Organizational structure and culture, as barrier to error detection and reduction, 908–909

Osteocalcin, in osteoporosis, 187–190

Osteoporosis, **175–197**

- biochemical markers for, 177–193
 - age-related changes in, 178–179
 - bone alkaline phosphatase isoenzyme, 187–188
 - bone sialoprotein, 180
 - collagen cross-links, 180, 182–187
 - deoxypyridinoline, 181–183, 186
 - osteocalcin, 187–190
 - pre-analytical issues in, 189, 191
 - principles of, 177–179
 - pyridinoline, 181–183, 186
 - tartrate-resistant acid phosphatase, 179–180, 182–183
 - telopeptides, 180, 182–187
 - urinary calcium, 179
 - uses of, 191–193
- causes of, 176
- development of, 175–176
- diagnostic methods for, 177
- epidemiology of, 176–177

Ovary, autoimmune disease of, 291–292, 294

Oxacillin, susceptibility testing of, 409–412

P

Paecilomyces infections, 701

Panton-Valentine leukocidin, as *Staphylococcus aureus* virulence factor, 407–409

Pap testing. *See* Cervical cancer screening.

Paragonimus infections, 748–749

Parasitic infections, emerging, **737–772**

- Babesia*, 757–760, 812–813
- Baylisascaris procyonis*, 746–748
- common, 738–744
- Cryptosporidium parvum*, 744–746
- epidemic, 744–746
- in blood supply, 757–763, 811–814
- in HIV infection, 740–742
- in travelers, 764–768
- Leishmania*, 764–766
- malaria. *See* Malaria.
- microsporidiosis, 742–744
- Paragonimus*, 748–749
- rare, 746–749
- Taenia*, 766–768

- Parasitic (*continued*)
 Third World, 750-757. *See also*
 Malaria.
Toxoplasma gondii, 740-742
Trichomonas vaginalis, 738-740
Trypanosoma brucei, 754-757
Trypanosoma cruzi, 760-763, 813-814
- Parathyroid hormone, **199-216**
 biochemistry of, 199-200
 measurement of, 200-203
 intraoperative, 204-212
 rapid, 208-210
 metabolism of, 199-200
- Parvovirus B19 infections, transfusion-transmitted, 802-803
- Patient identification errors. *See* Identification errors.
- Patient safety, error control in. *See* Error detection and reduction.
- Pediatric patients
 antibiotic-resistant Gram-negative bacteria in, **361-378**
 clinical consequences of, 365-366
 epidemiology of, 362-370
 in chronic care facilities, 370-371
 mechanisms of, 361-362
 outbreaks of, 366-367
 transmission of, 367-370
 familial medullary thyroid carcinoma in, 63-70
 growth hormone deficiency in. *See* Growth hormone, deficiency of.
 heart disorders in, ventricular B-type natriuretic peptide assays in, 259-260
- Penicillin(s)
 mechanism of action of, 428-429
 resistance to, in *Streptococcus pneumoniae*, 419-420
 susceptibility testing of, 501-528
- Penicillinases, 345-346
- Penicillin-binding proteins
 of respiratory pathogens, 429-433
 of *Staphylococcus aureus*, 403
- Penicillium marneffei* infections, 695, 703
- Pentagastrin, for calcitonin testing, 66-67
- Peptidases, in bacterial destruction, 428
- Peptidoglycan layer
 of *Staphylococcus aureus*, vancomycin resistance and, 383-384, 392-396
 of *Streptococcus pneumoniae*, 427-429
- Peroxidase-antiperoxidase method, for thyroglobulin, 31-32
- Pharmacokinetics and pharmacodynamics, of antimicrobial therapy for respiratory tract infections. *See under* Respiratory tract infections.
- Pheochromocytoma
 biochemical tests for, **85-103**
 diagnostic value of, 86-91
 metanephrines
 characteristics of, 92-95
 evolution of, 96-97
 plasma-free, 95-96
 specimens for, 98-99
 tandem mass spectrometry in, 97-98
 versus catecholamines, 91-92
 in multiple endocrine neoplasia type 2, 61-63
- Pig tapeworm infections, 766-768
- Pittsburgh Regional Health Care Initiative, 870, 872
- Pituitary gland
 dysfunction of, growth hormone deficiency in, 143-145, 166
 lymphocytic hypophysitis of, 295-296
- Plasma renin activity, in hyperaldosteronism, 109-110
- Plasminogen activator inhibitor type 1, in adipocytes, 225-226, 229
- Plasmodium* infections. *See* Malaria.
- Plesiomonas shigelloides* infections, 621-622
- Pneumocandins, resistance to, 725
- Pneumococci. *See* *Streptococcus pneumoniae*.
- Pneumocystis jiroveci* infections, 694, 696-697, 725
- Pneumonia
 amoxicillin/clavulanate for, 537-539, 541-544
 due to methicillin-resistant *Staphylococcus aureus*, 409
 epidemiology of, 529-530
- Pneumovirus infections, 777-778
- Point-of-care testing, **997-1022**
 adverse event reporting in, 1018
 competence assessment in, 1014
 definitions of, 998-1001
 errors in, 1005-1010
 causes of, 1002

- ethos for, 1012–1018
 - Kost's classification framework
 - for, 1005–1012
 - latent conditions predisposing to, 1002–1005
 - standard safety model for, 1002–1003
 - moderate-complexity testing category of, 999–1001
 - operator training for, 1013
 - patient identification in, 1015–1016
 - proficiency testing in, 1014–1015
 - provider-performed microscopy testing category of, 999, 1001
 - result reporting in, 1016
 - specimen acceptability for, 1016
 - supervision of, 1014
 - waved testing category of, 998–999, 1001
- Polyclonal antibody(ies), to thyroglobulin, 31–32
- Polyenes, resistance to, 723
- Polyglandular/polyendocrine syndromes, autoimmune
- type 1, 293–294, **305–317**
 - autoimmune regulator in, 307–313
 - clinical features of, 305–306
 - tests for, 313–314
 - type 2, 294–295, 305
 - type 3, 305
- Polymerase chain reaction
- for *Babesia*, 760
 - for beta-lactamases, 354–355
 - for *Chlamydomphila pneumoniae*, 635
 - for *Ehrlichia*, 642
 - for emerging pathogen detection, 572–573
 - for filoviruses, 774
 - for hantavirus, 776
 - for henipaviruses, 777
 - for *Leishmania*, 765
 - for malaria, 753
 - for *mec* gene, 412
 - for metapneumovirus, 778
 - for *Mycoplasma pneumoniae*, 633
 - for *Pneumocystis jiroveci*, 697
 - for Rickettsiae, 643–645
 - for SARS-coronavirus, 781
 - for thyroglobulin mRNA, 38–39
- Poole Therapeutic Outcome Model, for antibiotic efficacy evaluation, 492
- Population demographics and distribution, in emerging infections, 562–565
- Postanalytic errors
- definition of, 981
 - detection of, Q-PROBES and Q-TRACKS programs for, 974–975
 - frequency of, 1026
 - in point-of-care testing, 1006, 1009–1012
 - informatics for, 933–935
- Post-antibiotic effects, of antibiotics, 477
- Postlaboratory errors, definition of, 981
- Potassium analysis, potential errors in, 1029
- Poxvirus infections, 778–780
- Preanalytic errors
- definition of, 981
 - detection of, Q-PROBES and Q-TRACKS programs for, 967–972
 - frequency of, 1026
 - in point-of-care testing, 1005–1008, 1011
 - reduction of, 1027–1029
 - informatics for, 927–929
- Prelaboratory errors, definition of, 980
- Premature ovarian failure, in ovarian autoimmunity, 291–292, 294
- Preventable adverse event, definition of, 998
- Prion diseases, transfusion-transmitted, 814–817
- Process improvement, 919–920
- Proficiency testing, in point-of-care testing, 1014–1015
- Progesterone, 108
- Progestins, 108
- Prolactin, antibodies to, 7
- PROP1 protein, defects of, growth hormone deficiency in, 166
- Propranolol, thyroid function testing effects of, 26
- Prostate-specific antigen, immunoassay for, interference in, 12
- Protein synthesis inhibitors, in resistance, 436–440
- Protein tyrosine phosphatase-2 (ICA512/IA-2) autoantibodies, in diabetes mellitus, 281–282
- Provider-performed microscopy testing, 999, 1001

- Pseudallescheria boydii* infections, 700
- Pseudohyperkalemia, errors producing, 1029
- Pseudomonas aeruginosa*
in environment, 335–336
infections due to, antibiotic therapy for, 483
- Pseudomonas* infections
antibiotic-resistant, in pediatric patients, 361, 365–367
transfusion-transmitted, 809
- Public health systems, breakdown of, emerging infections due to, 576–578
- Public interest, in identification errors, 990
- Pulsed-field gel electrophoresis, for beta-lactamase identification, 354
- Puromycin, as protein synthesis inhibitor, 436
- Pyridinoline, in osteoporosis, 181–183, 186

Q

- Q-PROBES and Q-TRACKS programs, **965–978**
description of, 920–921, 965–967, 1030–1031
in analytical phase of testing, 972–974
in anatomic pathology error detection, 851, 854–856, 858
in postanalytical phase of testing, 974–975
in preanalytical phase of testing, 967–972
- Quality assurance, 919–920
- Quality control, in point-of-care testing, 1003, 1009
- Quality improvement, 919–920. *See also* Q-PROBES and Q-TRACKS programs.
- Quality management, in cervical cancer screening, in developing countries, 945–949
of cytology facilities, 950–953
of noncytologic methods, 956–959
- Quality System Regulation of 1996, 1030
- Quick-IntraOperative Intact PTH assay, 209–210
- Quinolones
for respiratory tract infections, 480–482
resistance to, 442
susceptibility testing of, 501–528

R

- Raccoons, *Baylisascaris procyonis* in, 746–748
- Radio frequency identification systems, 927, 993
- Radioassay, for glutamic acid decarboxylase antibodies, in diabetes mellitus, 280
- Radiobinding assay
for 3- β -hydroxysteroid dehydrogenase antibodies, in ovarian autoimmunity, 292
for ICA512 autoantibodies, in diabetes mellitus, 282
for transglutaminase antibodies, in celiac disease, 288–289
- Radioimmunoassays
for adipocytokines, 228
for hormones, interferences with, 2
for insulin antibodies, 282–283
for thyroglobulin, in thyroid carcinoma, 32–33
- Radiotherapy, for medullary thyroid carcinoma, 54
- Ramichloridium* infections, 704
- Rearranged in transfection gene. *See* RET gene.
- Record-keeping, in point-of-care testing, 1017
- Red tagging, in lean production system, 880–881
- Redundancy methods, for identification error reduction, 994
- Reduviidae, in American trypanosomiasis transmission, 760–763, 813–814
- Re-emerging infections, examples of, 560–561
- Reference Information Model, for data transmission, 917
- Regulations, on identification errors, 990
- Reporting. *See also* Communication; Informatics.
of errors
anatomic pathology, 849–850
failure to, 903–905
identification, 982–983
in point-of-care testing, 1018
of results
addenda and amendments in, 929–930
in point-of-care testing, 1016

- integrated, 930–932
 standardized, 914–915
 synoptic, 932–933
- Reporting systems, errors in, 974–975
- Resistance
 antifungal. *See* Antifungal agents, resistance to.
 antimicrobial. *See* Antimicrobial resistance.
- Resistin, in adipocytes, 224, 229
- Respiratory tract infections
 antimicrobial therapy for
 amoxicillin/clavulanate in, 536–544
 pharmacokinetics and pharmacodynamics of, **475–500**
 animal models of, 483–487
 combination, 487
 concentration-dependent killing, 480–481
 for optimization, 489–496
 mutant prevention concentration, 481–483
 obesity and, 487
 plasma vs. tissue concentrations, 485–487
 principles of, 476–480
 resistance and, 487–489
 epidemiology of, 529–530
- Respiratory tract pathogens. *See also specific organisms.*
 antibiotic-resistant, **417–451**
 mechanisms of, 427–443, 530–536
 beta-lactamases, 427–436
 DNA replication inhibition, 441–443
 folic acid metabolism inhibition, 443
 protein synthesis inhibition, 436–440
 prevalence of, 419–422, 530–536
 selection of, 423–426
- Restriction fragment length polymorphism testing, for mycobacteria, 651–652
- RET gene, mutations of
 in multiple endocrine neoplasia type 2, 57–60
 in pheochromocytoma, 61–62
 management based on, 68–74
 testing for, 64–66
- Retroviral infections,
 transfusion-transmitted, 800–801
- Reverse transcription-polymerase chain reaction, for thyroglobulin mRNA, 38–39
- Rheumatoid factor, interfering in hormone immunoassays, 9–10
- Rhinosinusitis
 amoxicillin/clavulanate for, 536–537, 539–544
 epidemiology of, 529–530
- Rhodotorula* infections, 707
- Ribosomal target site modification, in macrolide resistance, 454–458
- Rickettsial infections, 642–645, 810–811
- Rift Valley Fever, 826–828
- RNA analysis, 16s rRNA, for mycobacteria, 651
- Roche electrochemiluminescent method, for B-type natriuretic peptide, 245
- Rocky Mountain spotted fever, 642–645, 811
- Root cause analysis, for errors, 921–922
 in anatomic pathology, 857
 in cervical cancer screening, 953–956
- Roxithromycin, for respiratory tract infections, 486
- S**
-
- Saccharomyces cerevisiae*, resistance in, 725
- “Safe Practices for Better Health Care: A Consensus Report,” 918
- Safety, patient, error control in. *See* Error detection and reduction.
- Salmonella* infections
 food-borne, 567
 nontyphoidal, 609–612
 clinical features of, 610–611
 diagnosis of, 611
 epidemiology of, 610
 microbiology of, 609–610
 resistance in, 611–612
 treatment of, 611–612
- Salmonella* serotype Typhimurium infections, travel-associated, 568
- Sandfly, in *Leishmania* transmission, 764–765

- SARS (severe acute respiratory syndrome)-coronavirus infections, 576–577, 780–781, 803–804, 834–835
- Scantibodies assay, for parathyroid hormone, 202–203
- Scedosporium* infections, 700, 729–730
- Schmidt syndrome (autoimmune polyglandular syndrome type 2), 294–295, 305
- Scopulariopsis* infections, 701, 704
- Second opinion review, for postanalytic error detection, 933–934
- SEN virus infections, transfusion-transmitted, 800
- Sentinel events, definition of, 981
- Sepsis, from contaminated transfusion components, 808–810
- Serratia* infections
antibiotic-resistant, in pediatric patients, 361
colonization by, 369
epidemiology of, 362–363
outbreaks of, 366
transfusion-transmitted, 809
- Serum-concentration-time profile, of antibiotics, 475
- Seventh International Workshop on Multiple Endocrine Neoplasia recommendations, 70–73
- Severe acute respiratory syndrome (SARS), 576–577, 780–781, 803–804, 834–835
- Sex hormone-binding globulin
age-related changes in, 127
in obesity, 132–133
interfering in hormone immunoassays, 7–8
measurement of, 124
- Sexual behavior, emerging infections and, 565–566
- Shiga toxin-producing *Escherichia coli*. *See* *Escherichia coli* infections, O157:H7.
- Shionogi immunoradiometric assay, for B-type natriuretic peptide, 245
- Short stature, in growth hormone deficiency, 143–144
- Sialoprotein, bone, in osteoporosis, 180
- Single sign-on system, 928–929
- Six Sigma approach, to error analysis, 922–923, 1025–1026
- Skilled nursing facilities, antibiotic resistance in. *See* Elderly persons, in institutions, antibiotic resistance in.
- Skin infections, due to methicillin-resistant *Staphylococcus aureus*
examples of, 404, 406
genetic markers for, 408–409
outbreaks of, 406–407
virulence factors of, 408
- Sleeping sickness (African trypanosomiasis), 754–757
- Slips, definition of, 982
- Smallpox, 780
- Sodium iodide cotransporter, antibodies to
in Graves disease, 285
in thyroiditis, 287
- Soft-tissue infections, due to methicillin-resistant *Staphylococcus aureus*
examples of, 404, 406
genetic markers for, 408–409
outbreaks of, 406–407
virulence factors of, 408
- Somatomedin-C. *See* Insulin-like growth factor I.
- Special procedure reports, 930–932
- Specimens
acceptability of, in point-of-care testing, 1016
acquisition of, errors in, 970–972
identification errors involving. *See* Identification errors.
small sample volume of, in point-of-care testing, 1008
- Staphylococcal infections, emerging
coagulase-negative, 591–593
group A, 593–596
group B, 596–598
groups C and G, 598–599
- Staphylococcus aureus*
infections due to
antibiotic therapy for, 401, 478–480
antibiotic-resistant, 442, 576
emerging, 588–591
transfusion-transmitted, 809
methicillin-resistant, **401–416**
clinical significance of, 404–406
epidemiology of, 402–403
genetics of, 403, 408–409
mechanism of, 403–405

- outbreaks of, 406–407
 - rapid detection of, 412
 - susceptibility testing of, 409–411
 - virulence factors of, 407–408
 - vancomycin-intermediate, 383
 - vancomycin-resistant, **379–400**
 - COLVA strain, 392–396
 - development of, 384–385
 - genetic basis of, 389–392
 - mechanisms of, 383–384
 - Michigan isolate, 389–390
 - Pennsylvania isolate, 390–392
 - physiologic basis of, 392–396
 - resistant enterococci and, 380–382
 - susceptibility testing of, 385–389
 - Staphylococcus epidermidis* infections,
 - transfusion-transmitted, 809
 - STAT-IntraOperative-Intact-PTH kit, 209
 - Stem cell transplantation, fungal infections in, 695
 - Steroid 17 α -hydroxylase, antibodies to
 - in Addison disease, 290–291
 - in polyglandular syndromes, 306
 - Steroid cell autoantibodies, in ovarian autoimmunity, 291–292
 - Steroid hormones, **105–118**. *See also specific hormones.*
 - androgens, 107
 - clinical abnormalities of, 109–113
 - estrogens, 108
 - fate of, 108–109
 - glucocorticoids, 106–107
 - measurement of, 113–116
 - mineralocorticoids, 106
 - progestins, 108
 - transport of, 108–109
 - Streptococcus agalactiae* infections, 596–598
 - Streptococcus dysgalactiae* infections, 598–599
 - Streptococcus epidermidis* infections, 592–593
 - Streptococcus equi* infections, 598–599
 - Streptococcus* infections
 - of newborn, prophylaxis of, antibiotic resistance development in, 363–364
 - transfusion-transmitted, 809
 - Streptococcus iniae* infections, 599–600
 - Streptococcus pneumoniae*
 - antibiotic-resistant, 417
 - in pneumonia, 537–544
 - in rhinosinusitis, 536–537
 - macrolides, 453, 457, 459–464
 - mechanisms of, 427–433, 439–440, 442–443
 - pharmacokinetics and pharmacodynamics and, 487–488
 - prevalence of, 419–422, 495, 530, 533–536
 - susceptibility testing of, 501–515, 519–523
 - infections due to, antibiotic therapy for
 - animal models of, 483, 485–486
 - concentration-dependent killing in, 480–481
 - dosing in, 490–496
 - time-dependent, 478–480
 - susceptibility testing of, 501–515, 519–523
 - Streptococcus pyogenes*
 - infections due to, 483, 486, 593–596
 - macrolide-resistant, 453, 457, 459, 461, 463, 465
 - Streptogramins, as protein synthesis inhibitors, 437
 - Sulfamethoxazole, as folic acid metabolism inhibitor, 443
 - Supervision, in point-of-care testing, 1014
 - Surgery, fungal infections in, 693
 - Surgical pathology, identification errors in, 970, 987–988
 - Susceptibility testing. *See also* Antimicrobial resistance.
 - for antibiotic dose optimization, 332–333
 - of antifungal agents, 722
 - of *Haemophilus influenzae*, 501–511, 515–517, 520–523
 - of *Moraxella catarrhalis*, 501–507, 517–523
 - of *Staphylococcus aureus*
 - methicillin-resistant, 409–412
 - vancomycin-resistant, 385–389
 - of *Streptococcus pneumoniae*, 501–515, 519–523
 - Systemized Nomenclature of Medicine–Clinical Terms, 923–924
-
- T**
- Taenia* infections, 766–768
 - Tanapox infections, 779–780

- Tapeworm infections
Echinococcus multilocularis, 828-829
Taenia, 766-768
- Tartrate-resistant acid phosphatase, in osteoporosis, 179-180, 182-183
- Telithromycin, resistance to, mechanisms of, 457, 460
- Telopeptides, in osteoporosis, 180, 182-187
- Temafloxacin, for respiratory tract infections, 481
- Terminology, Systemized Nomenclature of Medicine-Clinical Terms, 923-924
- Testosterone, 107
 measurement of, 112, **119-139**
 bioavailable, 123
 for Leydig cell evaluation, 119-124
 free, 121-124
 in obesity, 130, 132-134
 total, 119-121
 transport of, 108-109
- Tetracyclines, as protein synthesis inhibitors, 436, 440
- Tetrahydrofolate reductase inhibitors, 443
- Thymus, autoimmune regulator protein in, 313
- Thyroglobulin, **29-47**
 antibodies to
 in autoimmune polyglandular syndromes, 294
 in Graves disease, 6, 285
 in thyroid carcinoma, 41-42
 in thyroiditis, 286-287
 interfering with assays, 36-38
 measurement of
 in serum, 32-38
 in thyroid carcinoma, 29, 31-32, 34, 38-42
 in tissue specimens, 31-32
 mRNA, 38-39
 physiology of, 29-31
 structure of, 29-30
 variant forms of, 35-36
- Thyroid cell bioassay, for thyroid-stimulating hormone receptor antibodies, 285-286
- Thyroid function testing, **19-28**
 drug effects on, 26-27
 in elderly persons, 24
 in hyperthyroidism, 25-26
 in hypothyroidism, 24-25
 in nonthyroidal illness, 27-28
 normal function and, 19-21
 procedures for, 21-22
 reference intervals for, 23
 screening, 22-23
- Thyroid gland
 autoimmune disease of, 284-287
 in autoimmune polyglandular syndromes, 305
 ovarian autoimmunity with, 291-292
 carcinoma of
 medullary. *See* Medullary thyroid carcinoma.
 thyroglobulin measurement in, 29, 31-32, 34, 38-42
 functional testing of. *See* Thyroid function testing.
- Thyroid peroxidase, antibodies to
 in autoimmune polyglandular syndromes, 294
 in Graves disease, 285
 in thyroiditis, 286-287
- Thyroidectomy, for medullary thyroid carcinoma, 53-54
 prophylactic, 67-75
- Thyroiditis, autoimmune, autoantibodies in, 286-287
- Thyroid-stimulating autoantibody, in Graves disease, 285
- Thyroid-stimulating hormone receptor, antibodies to, in Graves disease, 285-286
- Thyrotropin, measurement of
 drug effects on, 26-27
 for screening, 22-23
 in elderly persons, 24
 in hyperthyroidism, 26
 in nonthyroidal illness, 27-28
 interference in, 12-13
 methods for, 21-22
 reference interval for, 23
- Thyroxine
 measurement of, 21
 physiology of, 19-21
- Thyroxine-binding globulin, interfering in hormone immunoassays, 7
- Tick-borne infections
Anaplasma, 639-642, 811
Babesia, 757-760, 812-813
 bacterial, 810-811
Borrelia, 810-811
Ehrlichia, 639-642, 811
 rickettsial, 642-645, 810-811

- “To Err is Human: Building a Safer Health System,” 901, 913, 998, 1024
- Topoisomerases, inhibitors of, 441–442
- Total thyroxine, measurement of
methods for, 21
reference interval for, 23
- Total triiodothyronine, measurement of
methods for, 21
reference interval for, 23
- Toxic shock syndrome
staphylococcal, 407–408, 589–591
streptococcal, 595–596
- Toxoplasmosis, 740–742
- Toyota lean production system, 866–871
- Training, for point-of-care testing, 1003, 1013
- Transforming Health Care Quality through Information Technology, 924–925
- Transfusion(s)
HIV detection in, 1027
identification errors in, 983, 986–987
specimen collection errors in, 971–972
- Transfusion-transmitted infections,
emerging, **797–823**
bacterial, 808–810
Creutzfeldt-Jacob disease, 814–817
enteroviruses, 804–805
historical background of, 797–799
human herpes viruses, 801–802
human immunodeficiency virus, 800–801
human T-lymphotropic virus, 801
mosquito-borne viruses, 805–808
parasitic, 757–763, 811–814
parvovirus B19, 802–803
retrovirus, 800–801
SARS, 803–804
tick-borne, 810–811
viral hepatitis, 799–800
West Nile virus, 805–808
- Transglutaminase, antibodies to, in celiac disease, 288–289
- Transplantation, fungal infections in, 695–696
- Trauma, fungal infections in, 693
- Travelers, emerging infections carried by, 577
cholera, 568–569
in airplanes, 564
parasitic, 764–768
- Triazoles, resistance to, 724–725
- Trichomoniasis, 738–740
- Trichosporon* infections, 706–707, 723, 727
- Triiodothyronine
measurement of, 21, 27–28
physiology of, 19–21
- Trimethoprim, as folic acid metabolism inhibitor, 443
- Trimethoprim-sulfamethoxazole
resistance to, 495
susceptibility testing of, 501–528
- Tropheryma whippelii*, discovery of, 573
- Troponin, immunoassay for, interference in, 13
- Trypanosomiasis
African, 754–757
American (Chagas’ disease), 760–763, 813–814
- Tsetse fly, in African trypanosomiasis transmission, 754–757
- TT virus infections,
transfusion-transmitted, 800
- Tuberculosis, drug resistance in, 489
- Tumor markers, immunoassay for,
interference in, 12
- Tumor necrosis factor- α , in adipocytes, 224–225, 229
- Turbo intact PTH assay, 209–210
- Tyrosine hydroxylase, antibodies to, in autoimmune polyglandular syndromes, 294
-
- U**
-
- Uncertainty, intolerance of, 903–905
- Urine culture, specimen collection for,
errors in, 971
-
- V**
-
- Vaccination, refusal of, emerging infections and, 567
- Vaccinia virus infections (smallpox), 780
- Vancomycin, resistance to
in enterococci, 380–382, 575
in *Staphylococcus aureus*. See *Staphylococcus aureus*,
vancomycin-resistant.
- Vanillylmandelic acid, testing for, in pheochromocytoma, diagnostic value of, 87, 90–91

- Variant Creutzfeldt-Jacob disease, transfusion-transmitted, 814–817
- Velogene Rapid MRSA Identification Assay, for methicillin resistance, 412
- Ventricular B-type natriuretic peptide, in heart failure. *See under* Heart failure.
- Vibrio cholerae* infections. *See* Cholera.
- Vibrio parahaemolyticus* infections, 608
- Vibrio vulnificus* infections, 608–609
- Viral infections, emerging, **773–792**
 drug-resistant HIV, 773
 filoviruses, 773–774
 hantavirus, 570, 774–776
 henipavirus, 776–777
 influenza, 561, 574–575, 778
 metapneumovirus, 777–778
 poxviruses, 778–780
 severe acute respiratory syndrome (SARS), 576–577, 780–781, 803–804, 834–835
 West Nile virus, 781–783, 805–808

Virulence factors, *Staphylococcus aureus*, 407–408

Visceral leishmaniasis, 764–766

Vitek systems, for methicillin susceptibility, 410–411

W

- Waived testing, point-of-care, 998–999, 1001
- Waste, in anatomic pathology procedures, reduction of, 883, 886–887
- Water-borne infections, 567–569
 gram-negative. *See* Gram-negative bacteria, in emerging enteric infections.
- Web-based systems, for error detection and reduction, 858, 937–938
- West Nile virus infections, 781–783, 805–808
- Wet preparations, for *Trichomonas vaginalis*, 739

- Whole slide interinstitutional review, for postanalytic error detection, 933–934
- Williams micro-insulin autoantibody assay, 284
- Workflow, continuous, in lean production, for error reduction, 883, 886–887, 889, 891–897
- Wristband identification errors, 968–970, 985–986, 991–992, 1028

X

Xenodiagnosis, for *Trypanosoma cruzi*, 762

Y

- Yeast infections, emerging, 704–707
- Yersinia enterocolitica* infections, 618–620, 809

Z

- Zoonoses. *See also* Mosquito-borne infections; Tick-borne infections.
 emerging, **825–838**
 alveolar echinococcosis, 828–829
Baylisascaris procyonis, 746–748
 brand new agents in, 833–835
 Ebola virus, 773–774, 832–833
 hantavirus, 570, 774–776
 henipavirus infections, 776–777
 in new areas, 826–829
 in new species, 829–833
Leishmania, 764–765
 monkeypox infections, 778–779, 830–831
 Nipah virus, 776–777, 833–834
 Rift Valley Fever, 826–828
 severe acute respiratory syndrome (SARS), 576–577, 780–781, 803–804, 834–835
 tanapox infections, 779–780
 tick-borne. *See* Tick-borne infections.
- Zygomycetes infections, 693, 701–702, 723